ACOR Shares Outstanding History
Below is a table of the ACOR shares outstanding history going back to 2/19/2010:

Date ACOR Shares Outstanding
2/19/201038.16M
4/30/201038.72M
7/31/201038.88M
10/31/201039.08M
2/17/201139.10M
4/30/201139.46M
7/31/201139.66M
10/31/201139.67M
2/15/201239.70M
4/30/201240.10M
7/31/201240.09M
10/31/201240.16M
2/15/201340.28M
4/30/201340.57M
7/31/201340.69M
10/31/201341.27M
2/14/201441.31M
4/30/201441.65M
7/31/201441.74M
10/31/201441.95M
2/17/201542.58M
4/30/201542.79M
7/31/201542.85M
10/31/201543.16M
2/17/201645.75M
4/30/201646.07M
7/29/201646.14M
10/31/201646.11M
2/17/201746.41M
4/30/201746.66M
7/31/201746.65M
10/31/201746.75M
2/20/201846.91M
5/7/201847.07M
7/31/201847.48M
10/31/201847.56M
2/20/201947.63M
5/1/201948.13M
7/31/201948.11M
10/31/201948.03M

Also see: ACOR Market Cap History
and ACOR YTD Return
ACOR Historical Shares Outstanding:
+2.40% CAGR
ACOR Historical Shares Outstanding: +2.40% CAGR

Mouse over chart for data details
2/19/2010 ...10/31/2019
Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. is engaged in the commercial sales of Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Also, Co. markets branded Ampyra (dalfampridine), an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP) approved to improve walking in adults with multiple sclerosis. We show 40 historical shares outstanding datapoints in our coverage of ACOR's shares outstanding history.

Understanding the changing numbers of ACOR shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ACOR versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ACOR by allowing them to research ACOR shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for ACOR:
ACOR SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Acorda Therapeutics (ACOR) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

ACRS Shares Outstanding History
ACRX Shares Outstanding History
ACST Shares Outstanding History
ADMA Shares Outstanding History
ADMP Shares Outstanding History
ADMS Shares Outstanding History
ADPT Shares Outstanding History
ADRO Shares Outstanding History
ADUS Shares Outstanding History
ADVM Shares Outstanding History
More Healthcare companies »

 

ACOR Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.